Keith currently is responsible for leading early development Oncology programs through to clinical proof of concept. His role encompasses the oversight and leadership of several academic collaborations to further the understanding of biological mechanisms responsible for cancer disease progression and the emergence of drug resistance.
At Novartis, Keith previously led scientific evaluation and business development activity for multiple disease areas, and held roles heading DMPK discovery efforts for the Infectious Disease and CV/Metabolism areas. Prior to Novartis, Keith spent 9 years at Pfizer, involved in drug discovery/development and in establishing and leading academic research collaborations in areas such as tissue engineering, liver biology, and drug transporters.
Keith received his Ph.D. from UNC-Chapel Hill with a focus on mechanisms of hepatic transport and pharmacokinetics. He maintains an active academic role, lecturing at both MIT and Harvard University in these areas.